medicine beginner 10 sample questions

Oncology MCQ Practice Test

Cancer treatment approaches

Q1. A 55-year-old patient with advanced non-small cell lung cancer is being treated with a targeted therapy that inhibits the VEGFR pathway. Which of the following is a common side effect of this treatment?

Explanation: Targeted therapies that inhibit the VEGFR pathway can cause hypertension as a common side effect due to the inhibition of angiogenesis and the resulting increase in blood pressure.

Q2. A 45-year-old patient with metastatic breast cancer is being treated with a targeted therapy that inhibits the VEGFR pathway. Which of the following medications is most likely being used?

Explanation: Bevacizumab is a monoclonal antibody that specifically targets vascular endothelial growth factor (VEGF), making it a targeted therapy that inhibits the VEGFR pathway.

Q3. A 55-year-old patient with a history of smoking is diagnosed with stage IIIA non-small cell lung cancer. Which of the following is the primary goal of concurrent chemoradiation therapy in this patient?

Explanation: Concurrent chemoradiation therapy is a standard treatment approach for stage IIIA non-small cell lung cancer. The primary goal of this treatment is to improve overall survival by combining the cytotoxic effects of chemotherapy with the local control provided by radiation therapy.

Q4. A 65-year-old patient with metastatic renal cell carcinoma is being treated with a tyrosine kinase inhibitor. Which of the following is a common side effect of this class of medication?

Explanation: Tyrosine kinase inhibitors, such as sunitinib, can cause hypertension due to their effect on vascular endothelial growth factor receptors, leading to vasoconstriction and increased blood pressure.

Q5. A 65-year-old patient with a history of heavy smoking is diagnosed with non-small cell lung cancer (NSCLC) and has a tumor with a mutation in the epidermal growth factor receptor (EGFR) gene. Which of the following medications is a first-line treatment option for this patient?

Explanation: Afatinib is a targeted therapy that specifically inhibits the EGFR tyrosine kinase, making it a suitable treatment option for patients with NSCLC and an EGFR mutation. Crizotinib is used for ALK-positive NSCLC, pemetrexed is used for NSCLC in combination with a platinum-based chemotherapy, and nivolumab is used for various types of cancer, including NSCLC, but not specifically for EGFR mutation.

Q6. A 65-year-old patient with a history of smoking is diagnosed with stage III non-small cell lung cancer. Which of the following chemotherapy agents is most commonly used as a first-line treatment in combination with pembrolizumab?

Explanation: Pemetrexed is a folate antagonist that inhibits thymidylate synthase, leading to DNA damage and cell death. It is commonly used in combination with pembrolizumab for the first-line treatment of stage III non-small cell lung cancer.

Q7. A 65-year-old patient with metastatic colorectal cancer is being treated with a combination of chemotherapy and targeted therapy. The patient's tumor is found to have a mutation in the KRAS gene. Which of the following targeted therapies would be *least* appropriate for this patient?

Explanation: Panitumumab and Cetuximab are EGFR inhibitors and are ineffective in patients with KRAS mutations. Therefore, they are the least appropriate options for this patient.

Q8. A 65-year-old patient with a history of squamous cell carcinoma of the lung is undergoing chemotherapy. The patient's creatinine level has increased from 1.2 to 2.4 mg/dL after receiving carboplatin. Which of the following is the most likely cause of this patient's renal impairment?

Explanation: Carboplatin is a platinum-based chemotherapy drug that can cause nephrotoxicity, leading to renal impairment. The patient's elevated creatinine level is likely due to the nephrotoxic effects of carboplatin, rather than other potential causes such as thiamine deficiency or thrombotic microangiopathy.

Q9. A 65-year-old patient with metastatic renal cell carcinoma is being treated with sunitinib. Which of the following is a common side effect of this medication?

Explanation: Sunitinib is a tyrosine kinase inhibitor used in the treatment of renal cell carcinoma. It can cause hypertension as a common side effect due to its mechanism of action.

Q10. A 65-year-old patient with metastatic renal cell carcinoma is being treated with sorafenib. Which of the following is a common side effect of this medication?

Explanation: Sorafenib is a multikinase inhibitor used in the treatment of metastatic renal cell carcinoma. It is known to cause hypertension as a common side effect due to its mechanism of action.

That was just a sample. Sign up to unlock the full question bank with timed tests and certificates.

Sign Up Free
Oncology MCQ Practice Test | Mind Hustle